Actively Recruiting
Evaluation of DISC-0974 for Safety, Pharmacokinetics, and Clinical Activity in Adults with Myelofibrosis or Myelodysplastic Syndrome and Anemia
Led by Disc Medicine, Inc · Updated on 2026-10-22
150
Participants Needed
35
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 in people with myelofibrosis or myelodysplastic syndrome who also have anemia. This phase 1b2a open-label study aims to understand how DISC-0974 affects hematologic response in these participants, including its impact on anemia and transfusion dependence. DISC-0974 is given as a subcutaneous injection every four weeks during both the phase 1b dose-escalation and phase 2 expansion parts of the study. The study evaluates different cohorts based on transfusion dependence and anemia status, with doses administered repeatedly up to day 169. Participants continue stable dosing of other therapies for myelofibrosis as allowed, and certain washout periods are required before screening. Participants will be involved in regular assessments including blood and urine tests to monitor safety and treatment effects from day 1 through day 169. Researchers measure anemia response, transfusion independence, hematologic parameters, pharmacodynamics markers, and safety outcomes such as vital signs and adverse events. The study includes monitoring of quality of life related to anemia and fatigue. Overall participation may last several months, with detailed evaluations during treatment.
CONDITIONS
Brief Title
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Research Team
D
Disc Medicine Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here